Cardiac/mRNA vaccine research, part 3

Since my last entry on this subject on October 7, the flood of peer-reviewed publications on cardiac injury and mRNA vaccines has continued. I highlight the articles of particular interest along the way.

The quantity of articles addressing mRNA myocarditis appears to be increasing, from approximately one relevant article per day in September to two relevant articles per day in October and November. Once again, articles from MRI radiologists and cardiologists, particularly in pediatrics, predominate.

Yendrapalli’s case of post-Moderna heart failure in a previously healthy 69 year-old, who had persistent impairment of cardiac function five weeks later; Boudihi’s case of a 23 year-old male with myocardial infarction, heart failure, and no myocarditis one day after second covid vaccine dose; Kawano’s case of a 19 year-old male with myocarditis, cardiogenic shock, and appendicitis occuring 28 days after second Moderna dose; Miljoen’s careful study of 42 recreational athletes before and 1 week after their Pfizer booster dose, finding statistically significant decreased exercise tolerance (VO2Max) which was also clinically significant in 8 subjects, whose performance declined the equivalent to having aged ten years; Fujibayashi’s case of myocarditis in a 23 year-old male after dose 2 Moderna, in a man with prior history of viral myocarditis (patient advised to avoid additional mRNA covid vaccines afterward); Vivian’s case of chronically elevated troponin I and chest pain, without MRI abnormalities, following dose 2 Moderna; Kato’s meta-analysis of MRI characteristics in post mRNA vaccine myocarditis; AbdelMassih’s hypothesis that mRNA vaccines may activate latent host mRNA that predisposes to myocarditis; Ferchichi’s case series from Tunisia of 5 previously healthy patients who sustained myocarditis after covid vaccines (mRNA in 4 cases); MacKrill’s hypothesis that media attention to vaccine side effects in New Zealand was partly responsible for myocarditis reports via the “nocebo effect”; Phogat’s case of myocarditis in a 19 year-old, previously healthy male, onset two weeks after Pfizer booster, with recovery of ejection fraction after one month; Fenton’s editorial/review of myocarditis post mRNA vaccination; Naveed’s cohort study (published in Canadian Medical Association Journal) which estimated a relative risk of myocarditis in 18-29 year-old males after Moderna dose 2 at 148-fold over baseline; Verdecchia’s review of myocarditis and hypertension after mRNA vaccines; Corrao’s cohort study from Lombardy that attempted to calculate risk:benefit for young men receiving the Moderna vaccine, and found a negative risk-benefit for Moderna in 16-19 men; Baqi’s review of myocardial infarctions after covid vaccines; Taylor-Robinson’s first-person perspective (retired physician also) on cardiac complications after Moderna booster; Porcari’s editorial on mRNA vaccine myocarditis; Naveed’s cohort study from British Columbia that compared rates of myocarditis between Pfizer and Moderna; Witberg’s editorial calling for a “tailored approach” to mRNA vaccine administration; Seitz’s 33-patient case series of MRI findings in mRNA vaccine myocarditis, comparing them to viral myocarditis cases; Kravchenko’s editorial/review (in German) of MRI findings in mRNA myocarditis; Augustin’s cohort study (in German) using US health insurance databases that found highest myocarditis risk in young men; Musa’s analysis of most-cited articles on mRNA vaccines, which found that 3% of them addressed myocarditis; Manno’s pediatric 13-patient case series which showed improved but persistent MRI abnormalities in the majority of children who received MRI at 12 weeks post-myocarditis; Sanada’s case of myocarditis and POTS in a 13 year-old male following Pfizer dose 2; Frustaci’s editorial regarding myocarditis in covid and after mRNA vaccination; Saadi’s case from Saudi Arabia of a previously healthy 18 year-old male with myocarditis 4 days after Moderna dose 2; Voleti’s analysis of whether covid or mRNA vaccines is likelier to cause myocarditis; Hirsch’s case of a 59 year-old woman with fatigue several days after Pfizer dose 1, which worsened after dose 2, initially diagnosed as “long covid” and treated with an antidepressant, and later found via MRI to have myocarditis; Alhussein’s case series of 20 patients with mRNA myocarditis, reporting that “convalescent fibrosis was commonly observed, justifying ongoing need for clinical surveillance in this population”; Evertz’ comparison of 10 cases of mRNA myocarditis to 10 cases of viral myocarditis, which found few differences between groups; Brucato’s randomized controlled trial of interleukin-1 antagonist to prevent pericarditis from covid or mRNA vaccination; Masuda’s review of myocarditis after mRNA vaccination, and vaccine hesitancy; Abualenain’s survey of quality of information regarding mRNA vaccine myocarditis via standard browser searches; Pakanati’s case of 93 year-old female with stress-induced cardiomyopathy five days after mRNA vaccine dose 2; Del Grippo’s case series of pediatric patients post-mRNA myocarditis hospital discharge, which found that 3 of 12 patients had potentially hazardous arrhthymias on ambulatory monitoring;

(pause for breath - still 20 more articles to go…)